Skip to main content
. 2012 Apr 18;2012(4):CD003869. doi: 10.1002/14651858.CD003869.pub3

Komarnicky 1991

Methods RCT: enrolled: 859 evaluated: 779
Participants Inclusion: 1. Brain metastases with measurable disease 2. 18 to 75 years of age 3. KPS ≥ 40 4. Neurologic function class (NFC) 1, 2, 3 5. If on chemo must not have had change in drugs within two weeks prior to randomization, during RT/misonidazole or two weeks after completion of RT
Interventions 3000 cGy/10 fr and misonidazole versus 3000 cGy/10 fr
Outcomes 1. Survival
Notes QS = 3